MedPath

Minimally Invasive Interval Debulking Surgery in Ovarian Neoplasm: a Feasibility Study

Phase 2
Completed
Conditions
Effects of Chemotherapy
Peritoneal Cavity Cancer
Stage IV Ovarian Carcinoma
Registration Number
NCT02324595
Lead Sponsor
Catholic University of the Sacred Heart
Brief Summary

Phase II multicentric study

Detailed Description

The aim of this prospective Phase II multicentric study is to assess feasibility and early complications rate of "total laparoscopic/robotic" interval debulking surgery in patients with a clinical complete/partial response to neoadjuvant chemotherapy for advanced ovarian cancer.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
30
Inclusion Criteria
  • Age >18 years,
  • Advanced ovarian cancer submitted to neoadjuvant chemotherapy,
  • Clinical or serological complete/partial response (RECIST; GCIG),
  • PS ≤ 2 (ECOG),
  • Informed consent
Exclusion Criteria
  • Borderline and non-epithelial ovarian tumors,
  • Stable/progressive disease,
  • ASA 3-4,
  • Severe cardiopulmonary disease,
  • BMI > 40

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Operative complication rate30 days

Intra- and post-operative complication rate of total laparoscopic/robotic interval debulking surgery

Secondary Outcome Measures
NameTimeMethod
Overall SurvivalOne year

time to last follow up/death

Progression Free survivalone year

time to recurrence

Trial Locations

Locations (2)

Catholic University of Sacred Heart Rome,

🇮🇹

Rome,, Rome, Italy

Policlinico Agostino Gemelli

🇮🇹

Rome, Italy

Catholic University of Sacred Heart Rome,
🇮🇹Rome,, Rome, Italy

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.